Cargando…

Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients

Circulating cell-free DNA (ccfDNA) may contain DNA originating from the tumor in plasma of cancer patients (ctDNA) and enables noninvasive cancer diagnosis, treatment predictive testing, and response monitoring. A recent multicenter evaluation of workflows by the CANCER-ID consortium using artificia...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Leest, Paul, Boonstra, Pieter A., ter Elst, Arja, van Kempen, Léon C., Tibbesma, Marco, Koopmans, Jill, Miedema, Anneke, Tamminga, Menno, Groen, Harry J. M., Reyners, Anna K. L., Schuuring, Ed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281769/ https://www.ncbi.nlm.nih.gov/pubmed/32414097 http://dx.doi.org/10.3390/cancers12051222

Ejemplares similares

Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
por: van der Leest, Paul, et al.
Publicado: (2021)

Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
por: Tamminga, Menno, et al.
Publicado: (2019)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors
por: Boonstra, Pieter A., et al.
Publicado: (2018)

The potential of combined mutation sequencing of plasma circulating cell‐free DNA and matched white blood cells for treatment response prediction
por: van der Leest, Paul, et al.
Publicado: (2020)

Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patients
por: Tamminga, Menno, et al.
Publicado: (2020)

Immune microenvironment composition in non‐small cell lung cancer and its association with survival
por: Tamminga, Menno, et al.
Publicado: (2020)

Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch(®) and ISET
por: Tamminga, Menno, et al.
Publicado: (2020)

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
por: Boonstra, Pieter A., et al.
Publicado: (2020)

Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients
por: van der Leest, Paul, et al.
Publicado: (2023)

Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study
por: Lamy, Pierre-Jean, et al.
Publicado: (2020)

Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer
por: Saber, Ali, et al.
Publicado: (2016)

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
por: Koopman, Bart, et al.
Publicado: (2022)

Tyrosine kinase inhibitor sensitive PDGFRΑ mutations in GIST: Two cases and review of the literature
por: Boonstra, Pieter A., et al.
Publicado: (2017)

Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer
por: Donker, H. C., et al.
Publicado: (2023)

Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform
por: Bisschop, Cornelis, et al.
Publicado: (2018)

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC
por: Wei, Jiacong, et al.
Publicado: (2021)

A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
por: Koopman, Bart, et al.
Publicado: (2021)

Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material
por: Steeghs, Elisabeth M. P., et al.
Publicado: (2020)

A case report of an unusual non-mucinous papillary variant of CPAM type 1 with KRAS mutations
por: Koopman, Timco, et al.
Publicado: (2020)

Non‐small‐cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy
por: Koopman, Bart, et al.
Publicado: (2021)

Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling
por: Weber, Sabrina, et al.
Publicado: (2020)

Reinterpretation, reclassification, and its downstream effects: challenges for clinical laboratory geneticists
por: El Mecky, Julia, et al.
Publicado: (2019)

Comparative genome analysis of cortactin and HS1: the significance of the F-actin binding repeat domain
por: van Rossum, Agnes GSH, et al.
Publicado: (2005)

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
por: Wei, Jiacong, et al.
Publicado: (2018)

Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations
por: Koopman, Bart, et al.
Publicado: (2020)

The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015)

Subjective Mouthfeel and Temperature Alterations in COVID-19 Patients Six to Ten Months After Diagnosis
por: van Elst, Jip M., et al.
Publicado: (2022)

Effect of IKZF1 deletions on signal transduction pathways in Philadelphia chromosome negative pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
por: van der Sligte, Naomi E, et al.
Publicado: (2015)

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing
por: Saber, Ali, et al.
Publicado: (2016)

Cortactin overexpression results in sustained epidermal growth factor receptor signaling by preventing ligand-induced receptor degradation in human carcinoma cells
por: van Rossum, Agnes GSH, et al.
Publicado: (2005)

High Acute Myeloid Leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow
por: Weidenaar, Alida C., et al.
Publicado: (2011)

Drosophila Fascin is a novel downstream target of prostaglandin signaling during actin remodeling
por: Groen, Christopher M., et al.
Publicado: (2012)

Label-free enumeration, collection and downstream cytological and cytogenetic analysis of circulating tumor cells
por: Dhar, Manjima, et al.
Publicado: (2016)

Antigen-agnostic microfluidics-based circulating tumor cell enrichment and downstream molecular characterization
por: Cohen, Evan N., et al.
Publicado: (2020)

The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling
por: Van Deun, Jan, et al.
Publicado: (2014)

An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients
por: Wei, Jiacong, et al.
Publicado: (2020)

Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice
por: van Rossum, Agnes GSH, et al.
Publicado: (2006)

Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics
por: Eijkelenboom, Astrid, et al.
Publicado: (2019)

The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients
por: Van der Auwera, I, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_qg26u098jihbvje80spkcmkfr0